PDB18 COMPARISON OF RESOURCES UTILIZATION (RU)AND COST IN DRUG NAÏVE TYPE 2 DIABETES (T2D) PATIENTS TREATED WITH ROSIGLITAZONE (RSG)VS. SULFONYLUREA (SU) MONOTHERAPY  by Duh, MS et al.
size and dose spread assumptions. CONCLUSION: Cost of GH
waste can be an important consideration when evaluating GH
devices.
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OBJECTIVE: The objective of this study was to compare RU and
costs for drug naïve patients treated with RSG versus SU ﬁrst-line
monotherapy using real-world claims data. METHODS: Based
on medical, pharmacy, and disability insurance claims data
between October 2001 and December 2004, patients with a
diagnosis T2D who were newly initiated on an OAD, 18 years
old, and had 60 days of uninterrupted treatment were ana-
lyzed. Frequency of inpatient and outpatient visits and average
direct (inpatient, outpatient, and pharmacy) and indirect (work-
loss) costs were compared between the RSG and SU groups.
RESULTS: A total of 3377 RSG and 11,778 SU patients met
the inclusion criteria with RSG patients being younger (63.8 vs.
66.9 years, p < 0.001) with less co-morbidities (Charlson
co-morbidity index 0.95 vs. 1.23, p < 0.001) at baseline. During
treatment, RSG patients incurred fewer inpatient visits (0.47 vs.
0.77 visits per patient per year (PPPY), p < 0.001), outpatient
visits (17.0 vs. 17.9 visits PPPY, p < 0.001), and hospital days
(1.6 vs. 2.9 days PPPY, p < 0.001) than SU patients. The total
direct medical cost was lower in the RSG group ($1065 vs.
$1315 per patient per month (PPPM), p < 0.001) than the SU
group, including lower inpatient and outpatient cost ($717 vs.
$1046 PPPM, p < 0.001) but higher pharmacy cost ($348 vs.
$270 PPPM, p < 0.001). After taking into account the indirect
work-loss cost, the total direct and indirect cost was signiﬁcantly
lower in the RSG group ($1103 vs. $1355 PPPM, p < 0.001).
Multivariate analysis controlling for age, gender, co-morbidities,
and other covariates conﬁrmed that the RSG group was associ-
ated with a signiﬁcantly lower total cost than the SU group (cost
difference: $92.75 PPPM, p = 0.012). CONCLUSION: This
observational study of over 15,000 patients initiated on ﬁrst-line
monotherapy shows that RSG patients incur signiﬁcantly lower
resource utilization and costs than SU patients, outweighing
higher pharmacy cost.
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OBJECTIVE: Current treatment options for short children born
small for gestational age (SGA) are limited; however, the growth
hormone somatropin (Norditropin) has been shown to normalise
height in childhood and adolescence compared to no treatment.
The aim of this study was to establish whether somatropin (Nor-
ditropin) was a cost-effective treatment option for short children
born SGA compared to no treatment. METHODS: A decision
tree model was used to calculate the relative costs and health
beneﬁts associated with somatropin (Norditropin) treatment vs
no treatment over the lifetime of short children born SGA. The
analysis was undertaken from a UK National Health Service
(NHS) perspective; unit costs (GBP; 2007) were sourced from
relevant UK health care providers. Clinical effectiveness data
were taken from a long-term, multi-centre, double-blind, ran-
domised clinical trial comparing the effects of somatropin (Nor-
ditropin) to no treatment. Utility data was derived from a recent
UK-based study which assessed the relationship between short
stature and HRQoL. Sensitivity analyses were conducted to
assess the degree of uncertainty surrounding the data. RESULTS:
Over a patient’s lifetime, somatropin (Norditropin) (0.033 mg/
kg/day) was associated with an additional 2.74 quality-adjusted
life years (QALYs) and an incremental cost of GBP73,545 com-
pared with no treatment. As a result, somatropin (Norditropin)
was associated with an incremental cost per QALY of
GBP26,794 compared with no treatment. Probabilistic sensitivity
analysis, in which all parameters within the model were varied,
showed that there was a high probability that somatropin
(Norditropin) was cost effective compared to no treatment, based
on a willingness to pay threshold of GBP30,000 per QALY.
CONCLUSION: Based on a willingness to pay threshold
of GBP30,000 per QALY, somatropin (Norditropin) is a cost-
effective treatment strategy for short children born SGA, provid-
ing substantial incremental health beneﬁts at an additional cost.
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OBJECTIVE: Insulin detemir represents a class of long-acting
soluble insulin analogues intended to address basal insulin
requirements for patients with diabetes. Because direct acquisi-
tion costs of newer medications are higher than older insulin
treatments, payers are interested in their long-term value. This
study was conducted to quantify the long-term cost-effectiveness
of insulin detemir compared to intermediate-acting NPH insulin
for the treatment of T1DM in Canada. METHODS: The CORE
Diabetes Model was used to project lifetime clinical and eco-
nomic outcomes for T1DM patients on insulin detemir versus
NPH insulin. A slight advantage for insulin detemir in HbA1c
(-0.12%) and signiﬁcant reductions in major (69%) and minor
(25%) hypoglycemic events were modeled. These clinical
assumptions, as well as cohort characteristics (baseline age and
HbA1c of 27 and 8.9%, respectively), transition probabilities,
utilities, dis-utilities, direct treatment and complication costs
(from a Canadian provincial payer perspective) were derived
from recent published literature and on-line sources. Both clinical
and economic outcomes were discounted at 5% per annum.
RESULTS: Average total direct costs per patient were
CAN$88,403 for insulin detemir and CAN$76,551 for NPH
using a lifetime horizon. A 61% reduction in major hypoglyce-
mic events costs for detemir (CAN$765) vs. NPH (CAN$1965)
were observed. Quality-adjusted life years (QALYs) increased by
0.344 years (discounted) with detemir and were largely due to
decreased hypoglycemic events. The resulting incremental cost-
effectiveness ratio (ICER) for detemir vs. NPH was
CAN$34,418/QALY. CONCLUSION: The ICER obtained in
this analysis provides evidence for the long-term cost-
effectiveness of insulin detemir compared to NPH in T1DM and
is consistent with current Canadian standards. The overall value
of detemir was driven primarily by its favorable impact upon
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